Suppr超能文献

糖尿病与 COVID-19 患者预后的关联:一项回顾性研究。

The association of diabetes and the prognosis of COVID-19 patients: A retrospective study.

机构信息

Division of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave., Wuhan 430030, China.

Department of Endocrinology, Key Lab of Endocrinology, Ministry of Health, Peking Union Medical College Hospital (PUMCH), Chinese Academe of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Beijing 100730, China.

出版信息

Diabetes Res Clin Pract. 2020 Nov;169:108386. doi: 10.1016/j.diabres.2020.108386. Epub 2020 Aug 25.

Abstract

AIMS

This study evaluated the impact of previous glycemic control and in-hospital use of antidiabetic/antihypertensive drugs on the prognosis of COVID-19 patients with diabetes.

METHODS

In this retrospective cohort study, consecutive inpatients with laboratory confirmed COVID-19 were enrolled from Tongji Hospital (Wuhan, China). Patients without diabetes were matched to those with diabetes based on age, sex, and comorbidities. All patients were followed up to a clinical endpoint (discharge, worsening including transferring to ICU or immediate death). Data and outcomes were extracted from medical records and analyzed.

RESULTS

64 patients with pre-existing diabetes were included in this study, with 128 matched patients without diabetes included as a control group. Patients with diabetes had a higher rate of worsening (18.8% versus 7.8%, p = 0.025). Multivariable regression showed increased odds of worsening associated with previous glycemic control reflected by HbA1c (odds ratio 3.29, 95% CI 1.19-9.13, p = 0.022) and receiver-operating characteristics (ROC) curve identified HbA1c of 8.6% (70 mmol/mol) as the optimal cut-off value. Univariate analysis demonstrated the in-hospital use of antidiabetic/antihypertensive drugs were not associated with a higher risk of worsening.

CONCLUSIONS

COVID-19 patients with diabetes had a higher risk of worsening, especially those with poorly-controlled HbA1c, with an optimal cut-off value of 8.6%. The in-hospital use of antidiabetic/antihypertensive drugs were not associated with increased odds of worsening in patients with diabetes.

摘要

目的

本研究评估了既往血糖控制情况和住院期间使用降糖/降压药物对合并糖尿病的 COVID-19 患者预后的影响。

方法

在这项回顾性队列研究中,连续纳入了来自中国武汉同济医院的实验室确诊 COVID-19 住院患者。无糖尿病患者根据年龄、性别和合并症与糖尿病患者进行匹配。所有患者均随访至临床终点(出院、病情恶化,包括转入 ICU 或立即死亡)。从病历中提取数据和结局并进行分析。

结果

本研究纳入了 64 例患有糖尿病的患者,作为对照组纳入了 128 例匹配的无糖尿病患者。糖尿病患者的病情恶化率更高(18.8% vs. 7.8%,p=0.025)。多变量回归显示,既往血糖控制(HbA1c)与病情恶化的相关性更强(优势比 3.29,95%置信区间 1.19-9.13,p=0.022),ROC 曲线确定 HbA1c 为 8.6%(70mmol/mol)为最佳截断值。单因素分析表明,住院期间使用降糖/降压药物与病情恶化风险增加无关。

结论

COVID-19 合并糖尿病患者的病情恶化风险更高,尤其是 HbA1c 控制不佳的患者,最佳截断值为 8.6%。住院期间使用降糖/降压药物与糖尿病患者病情恶化风险增加无关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验